Episode

Closing Bell Overtime: AI, Markets and the Next Big Winners 6/1/26

Podcast
Closing Bell
Published
Jun 1, 2026
Duration seconds
2620
Processing state
not_requested
Canonical source
https://www.cnbc.com
Audio
https://dts.podtrac.com/redirect.mp3/cnbc.simplecastaudio.com/d13412e5-373f-49ef-b0d3-745a4f74427f/episodes/14c0775a-a9ee-4953-afe0-7969731e2f16/audio/128/default.mp3?aid=rss_feed&awCollectionId=d13412e5-373f-49ef-b0d3-745a4f74427f&awEpisodeId=14c0775a-a9ee-4953-afe0-7969731e2f16&feed=Nh1wIaXT
JSON
/v1/public/podcasts/closing-bell-5237668/episodes/closing-bell-overtime-ai-markets-and-the-next-big-winners-6-1-26
Markdown
/podcast/closing-bell-5237668/closing-bell-overtime-ai-markets-and-the-next-big-winners-6-1-26.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/closing-bell-5237668/episodes/closing-bell-overtime-ai-markets-and-the-next-big-winners-6-1-26/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/closing-bell-5237668/closing-bell-overtime-ai-markets-and-the-next-big-winners-6-1-26.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Our Kristina Partsinevelos breaks down Nvidia’s push into the PC market and explains why investors see it as a potential new catalyst after earnings. Then our Kate Rooney reports on Anthropic’s confidential IPO filing and brings reaction to the latest comments from OpenAI CEO Sam Altman. Dan Niles weighs whether the AI landscape is entering a new phase and identifies the winners and losers emerging across tech. Mike turns to the dashboard to track Berkshire Hathaway’s investment performance and a new position in homebuilder Taylor Morrison. Steve Wieting, Chief Investment Strategist at Citi Wealth, assesses the broader market outlook and where investors should focus next. Healthcare takes center stage as Angelica Peebles reports from ASCO with exclusive comments from Eli Lilly’s head of oncology. Jared Holz of Mizuho breaks down the biggest takeaways for biotech and pharmaceutical stocks.